Highly Pure, Arrayed Guide RNA for Streamlined Screening

Achieve Reliable Results From the Very First Screen!

 

Our long-time partner, TriLink BioTechnologies, provides ligation-based technology that delivers highly pure, arrayed guide RNAs, offering the consistency and precision researchers need for reliable high-throughput screening and early discovery applications.


Watch the video: Highly pure, reproducible guide RNA for CRISPR screening.

Consistency That Accelerates Discovery

Your screening success depends on data quality.

That’s why Tebubio partners with TriLink to bring you ligation-based gRNA synthesis that ensures uniform, well-to-well quality across each 96-well plate.

This level of consistency reduces technical noise, improves reproducibility, and enhances the accuracy of hit identification for downstream validation. With fewer failed replicates and cleaner datasets, you can streamline your workflows and accelerate lead candidate selection in your CRISPR programmes.

 

Figure 1: Ligation-based synthesis platform built for uniform, high-throughput gRNA production.

 

Figure 2: One SpCas9 and one SaCas9 gRNA ligated 16 times to demonstrate reproducibility of the ligation process. Each dot represents an average of triplicates (48 data points total).

 

Precision at the Plate

Every guide matters. TriLink's ligation-based synthesis ensures that each guide RNA on your plate is produced with the same high level of quality and performance.

 

The outcome:

  • Cleaner data
  • Fewer false positives
  • Greater confidence in every screening decision

 

 

 

 

High Purity, Low Variability

Reliable screening starts with purity and consistency. TriLink’s ligation-based synthesis delivers high-purity gRNAs with minimal variability from well to well and batch to batch.

This uniformity translates into consistent screening performance and greater confidence in your results.

 

 

Figure 3: Representative purity results for 96-well plate production of SpCas9 and SaCas9 gRNAs. Average purity values exceeded 80% for SpCas9 and 65% for SaCas9, verified by independent review.

 

FAQ

Find answers to the questions most frequently asked by our users, curated by our experts.

  • What is TriLink’s poly(A) tail modification?

    TriLink’s proprietary poly(A) modification is a small chemical moiety linked to the 3’-end of the poly(A) tail of mRNA after the in vitro transcription reaction. There are no other changes to the mRNA.

  • Do I need to change my coding sequence or DNA template to use TriLink’s poly(A) tail modification?

    No, the modification is not template-directed and occurs post-IVT. In this case, there is no need to change your DNA template, and there is no impact on the mRNA coding sequence.

  • Have you tested the tail modification with different poly(A) tail lengths and with different mRNA constructs of varying lengths?

    Yes, we have tested our proprietary poly(A) tail modification with different poly(A) tail lengths including 40A, 60A, 80A, 100A, and 120A. We have successfully added our Poly(A) tail modification to various mRNAs, such as eGFP, Fluc, mCherry, beta-gal, and Cas9 mRNA. These constructs range from 0.9 to 4.5 kb in length.

  • Do I need to change how I deliver the mRNA?

    TriLink’s poly(A) tail modification should be compatible with commonly used delivery vehicles. We have used it with common transfection reagents and LNPs, including LipofectamineTM MessengerMAXTM reagents, and ALC-0315, DSPC, Cholesterol, and DMG-PEG 2000: Pfizer/Acuitas Lipids.

  • Does the modification increase the immunogenicity or toxicity of the mRNA?

    We have not observed meaningful differences in the immunogenicity of tail-modified mRNA from non-tail-modified mRNA in our in vitro and in vivo studies.

  • Does the modification impact the integrity of my mRNA?

    No, we have data showing that the mRNA is of comparable integrity to regular oligo-dT-purified mRNA.

Name goes here

Position goes here

Description goes here

Small-Scale, High-Confidence Guides for Every Well

Available as custom, plate-based arrayed libraries of up to 96 sequences, these gRNAs are ideal for early-stage screening or pilot discovery studies.
Each guide is supplied in 2 nmol or 5 nmol yields, supporting efficient and cost-effective research design.

Key benefits:

  • Broad editing support: Compatible with Cas9, base editing, and CRISPRa/i

  • Flexible lengths: Up to 110 nt

  • Quality confirmed: Each guide verified by ESI-MS

  • Fast delivery: ~18 business days for the first plate, plus 3 days per additional plate

Speed That Drives Discovery

 

With Tebubio’s expertise in scientific support and TriLink’s proven synthesis platform, you’ll receive ready-to-screen, high-quality gRNAs in record time, keeping your discovery projects on track.

 

Tebubio: Your European Partner for Agile Biotech Solutions

As TriLink’s official EU distributor, Tebubio offers more than access: we provide expert support and local convenience.

  • Proximity: Based in Europe, we offer fast turnaround and easy communication.
  • Flexibility: Customisable services to fit your project needs, from early R&D to preclinical development.
  • Collaborative Approach: We work as an extension of your team, ensuring transparency and adaptability.
  • Scientific Expertise: Decades of experience in life sciences and drug delivery technologies.

Design Custom Arrayed gRNA Libraries Now

Contact us today to discuss your project needs, obtain detailed specifications, or arrange a bulk supply tailored to your specific study requirements.

Knowledge Resources – Expand Your Expertise

Stay at the forefront of mRNA research with Tebubio’s latest insights about TriLink’s products. Read our blogs:

  • References

    Article content created by Tebubio using courtesy materials provided by TriLink Biotechnologies.

Ready to discuss your project?

Complete the form below to start the conversation with our scientific experts.